Inventia Life Science
Melbourne, Australia· Est.
Inventia delivers high‑throughput 3D bioprinting platforms that generate assay‑ready disease models for faster, more predictive drug discovery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $55M
AI Company Overview
Inventia delivers high‑throughput 3D bioprinting platforms that generate assay‑ready disease models for faster, more predictive drug discovery.
OncologyNeurologyImmunology
Technology Platform
RASTRUM™ automated 3D bioprinting system that creates reproducible, assay‑ready micro‑tissues using proprietary hydrogel matrices for high‑throughput drug screening.
Opportunities
Expanding the 3D model library for emerging therapeutic areas and leveraging AI‑driven analytics to provide end‑to‑end drug discovery solutions.
Risk Factors
Adoption barriers in legacy pharma labs, competition from other 3D bioprinting firms, and potential regulatory scrutiny of model‑derived data.
Competitive Landscape
Key competitors include Organovo, Cellink, and Toxis; Inventia differentiates itself through high‑throughput plate formats, cloud‑based workflow integration, and a strong focus on reproducibility for phenotypic screening.